Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ROIV

ROIV - Roivant Sciences Ltd. Stock Price, Fair Value and News

$21.91-0.62 (-2.75%)
Market Closed

85/100

ROIV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

85/100

ROIV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$33.87

Target 3M

$28.22

Target 6M

$30.48

ROIV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ROIV Price Action

Last 7 days

-4.7%

Last 30 days

1.0%

Last 90 days

11.9%

Trailing 12 Months

96.5%

ROIV RSI Chart

ROIV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ROIV Valuation

Market Cap

15.2B

Price/Earnings (Trailing)

-37.57

Price/Sales (Trailing)

3.24

EV/EBITDA

-16.29

Price/Free Cashflow

-19.43

ROIV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$33.87

Target 3M

$28.22

Target 6M

$30.48

ROIV Fundamentals

ROIV Revenue

Revenue (TTM)

4.5B

Rev. Growth (Yr)

-96.83%

Rev. Growth (Qtr)

979.82%

ROIV Earnings

Earnings (TTM)

-405.6M

Earnings Growth (Yr)

50.68%

Earnings Growth (Qtr)

58.56%

ROIV Profitability

EBT Margin

-19.05%

Return on Equity

-9.3%

Return on Assets

-8.01%

Free Cashflow Yield

-5.15%

ROIV Investor Care

Buy Backs (1Y)

4.46%

Diluted EPS (TTM)

-0.56

ROIV Alerts

  • 4 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20244.5B000
202361.3M73.7M75.4M4.6B
202255.3M51.9M50.4M43.1M
202123.8M30.0M42.6M61.2M
202067.7M56.7M45.7M34.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Roivant Sciences Ltd.

ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
 CEO
 WEBSITEhttps://roivant.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES904

Roivant Sciences Ltd. Frequently Asked Questions

ROIV is the stock ticker symbol of Roivant Sciences Ltd.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Roivant Sciences Ltd. is 15.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ROIV's fair value in chart for subscribers.

The fair value guage provides a quick view whether ROIV is over valued or under valued. Whether Roivant Sciences Ltd. is cheap or expensive depends on the assumptions which impact Roivant Sciences Ltd.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ROIV.

As of Wed Jan 28 2026, ROIV's PE ratio (Price to Earnings) is -37.57 and Price to Sales (PS) ratio is 3.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ROIV PE ratio will change depending on the future growth rate expectations of investors.